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Abstract
Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis (CHR) and are associated
with altered neural responses to emotional stimuli in the striatum and medial temporal lobe. Using a randomised,
double-blind, parallel-group design, 33 CHR patients were randomised to a single oral dose of CBD (600 mg) or
placebo. Healthy controls (n= 19) were studied under identical conditions but did not receive any drug. Participants
were scanned with functional magnetic resonance imaging (fMRI) during a fearful face-processing paradigm.
Activation related to the CHR state and to the effects of CBD was examined using a region-of-interest approach.
During fear processing, CHR participants receiving placebo (n= 15) showed greater activation than controls (n= 19)
in the parahippocampal gyrus but less activation in the striatum. Within these regions, activation in the CHR group that
received CBD (n= 15) was intermediate between that of the CHR placebo and control groups. These findings suggest
that in CHR patients, CBD modulates brain function in regions implicated in psychosis risk and emotion processing.
These findings are similar to those previously evident using a memory paradigm, suggesting that the effects of CBD on
medial temporal and striatal function may be task independent.
Introduction
There are currently no licensed clinical interventions for
people at clinical high risk for psychosis (CHR)1,2. One of
the most promising candidate treatments is cannabidiol
(CBD), a phytocannabinoid constituent of the cannabis
plant3. While the main psychoactive cannabinoid in can-
nabis, delta-9-tetrahydrocannabinol (THC), has psychoto-
mimetic4–7 and potential anxiogenic effects, CBD is non-
intoxicating and has both anxiolytic8,9 and antipsychotic
properties10–12. However, the neural mechanisms of action
that underlie these effects are still unclear. In healthy
volunteers, CBD modulates neural responses to cognitive
and emotional tasks in several regions, particularly the
medial temporal cortex and the striatum, as well as func-
tional connectivity between these regions13–18. Similarly, in
clinical samples, CBD has been shown to modulate acti-
vation and functional connectivity between medial tem-
poral cortex and striatum during verbal memory
processing in people at CHR19 and those with established
psychosis20. Effects in these regions are of particular
interest as they are critically implicated in the onset of
psychosis21–26. However, whether the effects of CBD on the
medial temporal cortex and striatum in CHR subjects are
specific to verbal memory processing or are also evident in
the context of other cognitive or emotional processes
remains unclear.
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Emotional dysregulation is a common feature of the
CHR state and contributes to distress and to poor func-
tional outcomes27–31. Evidence suggests that CHR sub-
jects show altered neural responses to emotion (and
particularly fear) processing stimuli in limbic and para-
limbic regions (the hippocampus, parahippocampal gyrus
and amygdala), striatum and frontal cortex30,32,33.
Abnormal neurofunctional responses to emotional stimuli
in these regions may also underlie the high levels of
anxiety experienced by these patients and contribute to
the generation of attenuated psychotic symptoms by
fuelling aberrant salience28,30,34–37. CBD is known to have
anxiolytic effects in both animals and man10,38; offline
studies show that CBD reduces anxiety39 in people with
social anxiety disorder8,40 and in healthy people subjected
to experimental stress, such as simulated public speak-
ing41–43 (reviewed in ref. 10). CBD also attenuates the
anxiogenic effects of THC and modulates brain function
in the opposite direction during fear processing13,14,44. For
example, a previous study showed that the processing of
fearful (relative to neutral) faces under placebo conditions
is associated with activation in the parahippocampal gyrus
and amygdala, and while THC induced physiological
anxiety, CBD attenuated activation in these brain regions,
which was associated with a reduction of physiological
anxiety13. The anxiolytic properties of CBD are thus
potentially mediated by its effects on the same brain
regions that are altered in CHR patients.
The present study examined the effects of CBD on
regional brain activation in CHR subjects while they
viewed faces with fearful (vs neutral) expressions. On
the basis of data from previous studies (above), the two
primary regions of interest (ROIs) were the medial
temporal lobe (hippocampus, parahippocampal gyrus
and amygdala) and the striatum/pallidum (caudate,
putamen and globus pallidus). These regions are known
substrates of emotion (and particularly fear) proces-
sing45–47 and this task has previously been shown to
engage these processes and brain regions13. We first
hypothesised that, relative to healthy controls, CHR
patients under placebo conditions would show altered
engagement of the medial temporal lobe and striatum
during fear processing. Our second hypothesis was that
CHR patients receiving CBD would then show a ‘nor-
malisation’ of activation in the same regions identified as
differentially engaged in the placebo vs control analyses.
That is, activation in the CBD group would be inter-
mediate between that observed in the healthy control
and CHR placebo groups.
Patients and methods
Participants
The study received Research Ethics (Camberwell St
Giles) approval and all participants provided written
informed consent. Thirty-three antipsychotic-naive
CHR individuals, aged 18–35 years, were recruited from
specialist early detection services in the United King-
dom. CHR status was determined using the Compre-
hensive Assessment of At-Risk Mental States
(CAARMS) criteria48. Briefly, subjects met one or more
of the following subgroup criteria: (a) attenuated psy-
chotic symptoms, (b) brief limited intermittent psy-
chotic symptoms (psychotic episode lasting <1 week,
remitting without treatment), or (c) either schizotypal
personality disorder or first-degree relative with psy-
chosis, all coupled with functional decline48. Nineteen
age- (within 3 years), sex- and ethnicity-matched
healthy controls were recruited locally by advertise-
ment. Exclusion criteria included history of psychotic
or manic episode, current Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition diagnosis
of substance dependence (except cannabis), intelligence
quotient <70, neurological disorder or severe inter-
current illness and any contraindication to magnetic
resonance imaging (MRI) or treatment with CBD.
Inclusion/exclusion criteria were pre-specified. Parti-
cipants were required to abstain from cannabis for 96 h,
other recreational substances for 2 weeks, alcohol for
24 h and caffeine and nicotine for 6 h before attending.
A urine sample prior to scanning was used to screen for
illicit drug use and pregnancy.
Design, materials, procedure
The study was registered (ISRCTN.org identifier:
ISRCTN46322781) and the protocol (including power
calculation) has been previously published (supplement in
ref. 19).
Using a randomised, double-blind, placebo-controlled,
three-arm, parallel-group design, CHR participants were
randomised to a single oral 600 mg dose of CBD (THC-
Pharm, Germany) or a matched placebo capsule. This
dose was selected based on previous findings that doses of
600–800 mg/day are effective in established psychosis11
and anxiety8,10,49. Psychopathology was measured at
baseline (before drug administration) using the CAARMS
(positive and negative symptoms) and State-Trait Anxiety
Inventory (State Subscale). Following a standard light
breakfast, participants were administered the capsule (at
~11 a.m.) and, 180 min later, underwent functional MRI
(fMRI) while performing a fearful faces task. This interval
between drug administration and fMRI acquisition was
selected based on previous findings describing peak
plasma concentrations at 180min following oral admin-
istration50,51. Control participants were investigated under
identical conditions but did not receive any study drug.
Plasma CBD levels were sampled at baseline (before tak-
ing the study drug) and at 120 and 300min after drug
administration.
Davies et al. Translational Psychiatry          (2020) 10:311 Page 2 of 12
Functional MRI
Image acquisition
All scans were acquired on a General Electric Signa HDx
3 T MR system. Functional images were acquired using
echo planar imaging (EPI) with parameters: repetition time
(TR)= 2000ms, echo time (TE)= 30ms, flip angle= 75°,
39 × 3mm slices, 3.3mm slice gap, matrix= 64 × 64, field
of view (FoV)= 240, 180 timepoints. T1-weighted struc-
tural images (inversion recovery EPI; TE= 30ms, TR=
3000ms, 43 × 3mm slices, FoV= 240mm, matrix=
128 × 128) were also acquired for co-registration.
fMRI task
Participants were studied in one 6-min fMRI experi-
ment while performing a fearful face processing task
(described in detail elsewhere13,14,52). In short, the blood-
oxygen-level-dependent (BOLD) haemodynamic response
was measured using an event-related design while sub-
jects viewed fearful faces (mild fear, intense fear), which
were contrasted with faces with neutral expressions. Ten
different facial identities each conveying a neutral, mild
fear and intense fear expression (30 different facial sti-
muli) were presented twice each for 2 s, resulting in 60
facial stimuli in total. The order of presentation of facial
identities and expression type was pseudorandomised
such that the same identity or expression type was not
presented in successive trials. The inter-trial interval was
varied from 3 to 8 s according to a Poisson distribution,
with an average interval of 4.9 s. A fixation cross was
presented during the inter-stimulus interval. Participants
were asked to indicate the gender of the face via button
press, with the speed and accuracy of responses recorded
online throughout image acquisition.
Analysis
fMRI data were analysed with the XBAM software v4.1
using a nonparametric approach to minimise assump-
tions53,54. For each group (control, placebo, CBD), we con-
trasted the active task condition (mild and intensely fearful
faces) against the baseline condition (neutral faces) to
identify the brain regions engaged by the processing of fear
after controlling for activation related to face processing
independent of emotional expression.
Images were corrected for motion55 and smoothed with
a 5-mm Gaussian filter. Individual activation maps were
created using two γ-variate functions to model the BOLD
response56. Following a least-squares fitting of this model,
the sum of squares (SSQ) ratio statistic (ratio of the model
component to the residual sum of squares) was estimated
at each voxel, followed by permutation testing to deter-
mine significantly activated voxels specific to each con-
dition (neutral, mild fear, intense fear)57,58. SSQ ratio
maps for each individual were transformed into standard
stereotactic space54,59. Group activation maps for each
condition (and then for neutral vs mild fear and neutral vs
intense fear) were computed for each group (control,
CBD, placebo) by determining the median SSQ ratio at
each voxel (over all individuals). Mild and intense fear
were thereafter analysed as a single fearful faces condition.
Group activation maps for fearful vs neutral conditions
were compared between participant groups (placebo vs
control) or treatment conditions (CBD vs placebo) using
nonparametric analysis of variance (ANOVA)53 and an
ROI approach. A single ROI mask was constructed using
the Talairach atlas daemon, which included the bilateral
medial temporal lobe (hippocampus, parahippocampal
gyrus and amygdala) and the striatum/pallidum (caudate,
putamen and globus pallidus). These regions were selec-
ted a priori based on our previous findings19. The voxel-
wise statistical threshold was set at p= 0.05, and the
cluster-wise thresholds were adjusted to ensure that the
number of false-positive clusters per brain would be <1;
clusters that survived this critical statistical threshold and
the corresponding p values are reported.
In line with our first hypothesis, we first compared the
placebo-treated CHR group with healthy controls to
identify areas (within our pre-defined ROI network)
showing altered activation related to the CHR state. We
then directly compared CHR patients under placebo with
those under CBD (within the same pre-defined ROI net-
work) to test whether CBD had effects on the same brain
regions that were identified as having altered activation
associated with CHR status (as in the comparison of
placebo-treated CHR participants with healthy controls
above). Finally, to test the hypothesis that activation in the
CBD group would be intermediate between that of the
control and placebo groups, we examined whether a linear
relationship in brain activation (placebo group > CBD
group > control group or placebo group < CBD group <
control group) existed within the same ROI network.
Behavioural task analyses
All non-imaging data were analysed using SPSS 24.
Extreme values (>3 × interquartile range identified in
boxplots) within the behavioural task data were excluded
from task performance analyses. The percentage of cor-
rect responses and reaction times were analysed using
mixed ANOVAs, with group (control, placebo, CBD) as
the between-subject factor and emotional valence (neu-
tral, fearful) as the within-subject factor. Robustness of
findings to outliers was tested using sensitivity analyses.
Significance was set at p < 0.05.
Results
There were no between-group differences in the
majority of demographic and baseline clinical character-
istics, except for fewer years of education in the placebo
group relative to controls (Table 1). In the CBD group,
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mean plasma CBD levels were 126.4 nM (SD= 221.8) and
823.0 nM (SD= 881.5) at 120 and 300 min after drug
intake, respectively. Three CHR individuals exited the
scanner prior to the fMRI task, leaving 15 subjects in the




One subject from each group had no useable offline task
data and one healthy control was removed due to extreme
low task performance (gender discrimination accuracy)
values, leaving 14 participants in the placebo group, 14 in
the CBD group and 17 controls for task accuracy and
reaction time analyses. Subjects distinguished the gender
of faces with a percentage mean ± SD accuracy of 87.94 ±
2.25 in controls, 88.33 ± 2.61 in the placebo group and
86.07 ± 3.96 in the CBD group. There was no main effect
of group, valence or a group × valence interaction on task
performance (all p > 0.05). Removal of outliers made no
material change to the results.
Reaction times
Across all individuals, there was a significant main effect
of valence (F(1,43)= 8.47, p= 0.006) with subjects
responding significantly faster (in gender discrimination)
to fearful relative to neutral faces. There was no main
effect of group (F(2,43)= 2.71, p= 0.078) and no inter-
action between group and valence (F(2,43)= 2.09,
p= 0.137). After removal of one potential outlier, the
Table 1 Sociodemographic and clinical characteristics at baseline.
Characteristic CBD (n= 16) Placebo (n= 17) Control (n= 19) Pairwise comparison
Control vs placebo Placebo vs CBD
Age, years; mean (SD) 22.7 (5.08) 24.1 (4.48) 23.9 (4.15) p= 0.91a p= 0.42a
Sex, N (%) male 10 (62.5) 7 (41.2) 11 (57.9) p= 0.32b p= 0.22b
Ethnicity, N (%)
White 10 (62.5) 7 (41.2) 11 (57.9) p= 0.59b p= 0.43b
Black 2 (12.5) 5 (29.4) 5 (26.3)
Asian 0 (0) 1 (5.9) 0 (0)
Mixed 4 (25) 4 (23.5) 3 (15.8)
Education, years; mean (SD) 14.4 (2.71) 12.6 (2.76) 16.9 (1.58) p < 0.001a p= 0.06a
CAARMS score, mean (SD)
Positive symptoms 40.19 (20.80) 42.94 (29.47) NA NA p= 0.76a
Negative symptoms 23.25 (16.49) 28.41 (20.49) NA NA p= 0.43a
STAI-S, mean (SD) 40.31 (9.07) 38.94 (10.18) NA NA p= 0.69a
Urine drug screen results, N (%)
Clean 10 (63) 8 (47) 0 (0) NAc p= 0.45b
THC 2 (13) 5 (29) 0 (0)
Morphine 1 (6) 0 (0) 0 (0)
Benzodiazepines 0 (0) 1 (6) 0 (0)
PCP 0 (0) 1 (6) 0 (0)
Missing 3 (19) 2 (12) 0 (0)
Current nicotine use, N (%) yes 9 (56.3) 5 (29.4) 2 (10.5) p= 0.15b p= 0.12b
Current cannabis use, N (%) yes 7 (43.8) 7 (41.2) 0 (0)d NAc p= 0.88b
Handedness, N (%) right 14 (87.5) 17 (100) 18 (94.7) p= 0.37b p= 0.16b
CAARMS Comprehensive Assessment of At-Risk Mental States, CBD cannabidiol, CHR clinical high risk for psychosis, N number of subjects, NA not applicable, PCP
phencyclidine, STAI-S State-Trait Anxiety Inventory-State Subscale, THC Δ9-tetrahydrocannabinol.
aIndependent t test.
bPearson chi-squared test.
cControls were selected to have minimal drug use and hence were not compared with CHR participants on these parameters.
dCannabis use <10 times lifetime (no current users).
Bold text indicates significant difference.
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main effect of group became significant (F(2,42)= 4.96,
p= 0.012), with healthy controls responding significantly
faster than the CBD group.
fMRI results
Task network in healthy controls
In healthy controls, decreased activation was observed
in the left parahippocampal gyrus during the processing of
fearful relative to neutral faces (peak Talairach coordi-
nates x=−25, y=−41, z=−7; k= 17; p < 0.001). There
were no significant effects in the opposite direction
(fearful > neutral faces).
Differences in activation associated with the CHR state
(placebo vs controls)
During the processing of fearful relative to neutral
faces, compared to healthy controls, CHR subjects
receiving placebo showed augmented activation in the
left lingual gyrus and bilateral parahippocampal gyri and
attenuated activation in the striatum bilaterally, including
the left caudate head and putamen, the right putamen
and a smaller cluster in the right caudate head (Table 2
and Fig. 1).
Effects of CBD on activation in participants at CHR
(CBD vs placebo)
During fear processing, compared to CHR participants
receiving placebo, those in the CBD group showed lower
activation in the left parahippocampal gyrus and in a small
cluster in the left amygdala and greater activation in the
left putamen and in the right putamen extending to the
caudate head (Table 2 and Fig. 1).
Between-group linear analysis
This analysis identified clusters where the pattern of
regional brain activation during fear processing showed a
linear relationship across the three groups, such that
activation in the CBD group was intermediate to that of
the placebo and control groups. A linear relationship was
observed in relatively large clusters in the bilateral para-
hippocampal gyri, with the greatest activation in the
group of CHR participants receiving placebo, the lowest
in healthy controls and intermediate activation in the
CBD group (Table 3 and Fig. 2). These clusters directly
overlapped with the parahippocampal clusters differen-
tially engaged by the control and placebo groups in the
two-group analyses. The opposite linear pattern was
observed in the striatum. Here the highest level of acti-
vation was found in healthy controls, the lowest in CHR
participants receiving placebo and intermediate activation
in the CBD group (Table 3 and Fig. 2). Again, these
clusters directly overlapped with the clusters found to be
differentially engaged in the placebo vs healthy control
group analyses. Removal of the healthy control subject
with extreme low task performance (accuracy) scores
made no material change to the imaging results (data not
shown here).
Discussion
We investigated differences in brain function during
fear processing between CHR subjects and healthy con-
trols and examined the effects of a single dose of CBD. As
expected, relative to healthy controls, CHR individuals
under placebo conditions showed attenuated striatal and
augmented parahippocampal activation during fear pro-
cessing. The major finding of the present study was that,
as predicted, a single dose of CBD modulated activation in
these regions such that activation in the CHR subjects
given CBD was intermediate to that observed in CHR
subjects given placebo and the healthy controls.
These results are broadly consistent with those from a
previous study19, wherein we examined the same indivi-
duals under identical conditions, except that activation
was measured during a verbal memory task, rather than
an emotional processing task. In both studies, we find that
CBD modulated parahippocampal and striatal activa-
tion19. Moreover, the direction of the effects of CBD in
both studies were such that they reflected a normalisation
of the dysfunction observed in the respective CHR-
placebo vs control group analyses. CBD has also been
found to attenuate dysfunction of mediotemporal
Table 2 Differences in activation between 15 participants
at clinical high risk for psychosis (CHR) receiving placebo,








Differences between healthy controls and CHR-placebo
Placebo > controls
Parahippocampal gyrus −18 −33 −13 5 0.002
Parahippocampal gyrus −25 −44 −7 35 <0.001
Parahippocampal gyrus 18 −33 −3 22 <0.001
Lingual gyrus −22 −56 3 5 0.003
Controls > placebo
Putamen −22 11 0 5 0.002
Caudate head −11 19 0 10 <0.001
Putamen 25 11 3 7 0.001
Putamen 22 15 0 13 <0.001
Differences between CHR-placebo and CHR-CBD
Placebo > CBD
Amygdala −25 −4 −16 4 0.002
Parahippocampal gyrus −18 −56 −7 11 <0.001
CBD > placebo
Putamen 25 15 0 6 0.001
Putamen −18 11 7 16 <0.001
aCorrected for <1 false-positive cluster.
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activation and mediotemporal–striatal functional con-
nectivity during memory processing in patients with first-
episode psychosis20. Taken together, the data from the
present study extends previous results to suggest that the
acute effects of CBD on activation in the medial temporal
cortex and striatum, key brain regions implicated in the
onset of psychosis22–24, may be task independent. How-
ever, the precise direction of effects of CBD in these
regions differ between the two CHR studies (further dis-
cussed below).
Previously, during a verbal memory task, we found that
CHR individuals under placebo conditions showed less
activation in the caudate (during encoding) and in the
parahippocampal gyrus (during recall) compared to con-
trols, and CBD augmented activation in both regions19. In
contrast, during fear processing in the present study, CHR
individuals showed reduced activation in the striatum and
enhanced activation in the parahippocampal gyri com-
pared to controls, and CBD attenuated parahippocampal
activation while augmenting striatal activation. The pri-
mary between-study difference in the direction of CBD
effects therefore appears in the medial temporal lobe,
which may be accounted for by the differential role of this
region in verbal memory vs fear processing paradigms. In
verbal memory processing, the parahippocampal gyrus is
involved in the binding of contextual and relational
information to support memory encoding and recall60,61.
Recall performance was found to be correlated with
parahippocampal engagement19, suggesting that in the
context of pathology/insufficient recruitment of this
region to meet mnemonic demands, CBD may act to
optimise parahippocampal engagement. This accords with
Fig. 1 Altered brain activation in participants at clinical high risk of psychosis (CHR) and effect of cannabidiol (CBD). a Fear processing in the
CHR-placebo vs control group. Clusters showing greater (red/yellow) or reduced (blue/green) activation in participants at clinical high risk receiving
placebo compared with healthy controls during fear processing. b Fear processing in the CHR-CBD vs CHR-placebo group. Clusters showing greater
(red/yellow) or reduced (blue/green) activation in participants at clinical high risk receiving cannabidiol (CBD) compared with those receiving
placebo during fear processing. The right side of the brain is shown on the right of the images.
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the finding that CBD protects verbal memory against the
detrimental effects of THC6 and partially normalises
aberrant brain function during memory processing in
first-episode psychosis20. Conversely, during fear proces-
sing, the parahippocampal gyrus and amygdala are known
to activate in response to fear/threat-related environmental
cues, particularly angry or fearful facial stimuli45–47. In the
current study, both parahippocampal and amygdala acti-
vation were attenuated by CBD, suggesting that CBD may
partially normalise (attenuate) the altered neurofunctional
response to fear/threat-related stimuli in CHR patients,
which is in line with the potential anxiolytic effects of CBD
and the role of the endocannabinoid system as a regulator
of subjective affective states, including anxiety, fear and
aggression62–64. Indeed, previous work has shown that CBD
attenuates limbic and paralimbic function in healthy indi-
viduals13,65 and in patients with anxiety disorders9, and this
is related to its anxiolytic effects9,13. In terms of more
general anxiolytic effects, offline studies show that CBD
reduces anxiety39 in people with social anxiety disorder8,40
and in healthy people subjected to experimental stress, such
as simulated public speaking41–43 (reviewed in ref. 10).
Consistent with this, we recently found that a short (7 day)
course of CBD treatment partially attenuated abnormal
neuroendocrine (cortisol) and psychological (anxiety and
stress perception) responses to experimentally induced
social stress in CHR patients66. Together, these findings
support further research into the potential utility of CBD for
ameliorating anxiety both within and outside of CHR
populations. Whether the effects of CBD in CHR indivi-
duals arise through the specific targeting of psychosis-
related pathophysiology or are due to more generic effects
(for instance, on state anxiety) remains an important avenue
for future research.
Our findings also agree with what is known about the
opposite effects of THC and CBD on emotion-processing-
related circuitry in healthy people. In the majority of (but
not all67,68) studies, THC appears to augment amygdala
activation and increase anxiety during fearful face pro-
cessing14,62 and reduces amygdala–prefrontal connectivity
during negative affect reappraisal62. Conversely, CBD
increases fronto-striatal connectivity69 and attenuates
amygdala activation while concomitantly decreasing
physiological anxiety13,14. Some (but not all70) offline
studies also show that CBD improves emotional face
recognition while THC impairs it, and combining CBD
with THC prevents the impairing effects of THC71.
The finding that CHR patients show alterations in brain
function during fear processing is consistent with pre-
vious work showing dysfunction in medial temporal and
striatal regions in CHR individuals across numerous
cognitive paradigms19,72–74, as well as evidence of elevated
limbic response in those with psychosis-spectrum fea-
tures35 and individuals at genetic risk75, and altered
amygdala/hippocampal activation in those with estab-
lished psychosis76,77. Meta-analyses of >100 fMRI data
sets indicate that the parahippocampal gyrus is active
during the processing of emotional faces46, and emotion
(particularly fear) processing in humans is associated with
increased dopamine neurotransmission in the para-
hippocampal gyrus and striatum47. Enhanced para-
hippocampal activation in CHR individuals in the present
study may therefore reflect an overactivation to emotional
stimuli, in keeping with the notion that hippocampal
hyperactivation is critical to psychosis onset21–23,26, and is
consistent with previous evidence of elevated limbic
response in those with psychosis-spectrum features35 and
individuals at genetic risk75. The enhanced activation in
the current study may also reflect a failure to deactivate
limbic and paralimbic regions after repeated presentations
of fear/threat-related stimuli78,79, as has been suggested80.
Attenuated activation in the striatum in CHR indivi-
duals may reflect disrupted emotional salience processing.
A study of emotional prosodic voice recognition found
that in healthy controls the caudate was activated in
response to negative (vs neutral) stimuli, whereas CHR
individuals showed the opposite pattern: greater activa-
tion to neutral stimuli32. These findings echo further work
showing that CHR individuals hyperactivate frontal and
temporal regions in response to neutral (vs emotional)
faces33, and greater corticolimbic activation to neutral (vs
emotional) scenes is associated with higher levels of
positive symptoms and poorer functioning in CHR
patients30. This phenomenon is also observed in the
hippocampus and amygdala in patients with established
psychosis81. Conceptually, fearful facial stimuli are
Table 3 Linear relationship in activation across 15
participants at clinical high risk for psychosis (CHR)
receiving placebo, 19 healthy controls and 15 CHR








Placebo > CBD > controls
Parahippocampal gyrus −25 −44 −7 37 <0.001
Parahippocampal gyrus 18 −33 −3 25 <0.001
Controls > CBD > placebo
Putamen −18 7 −3 5 0.001
Caudate head −7 19 0 10 <0.001
Putamen 22 15 0 11 <0.001
Putamen 25 4 3 8 0.001
aCorrected for <1 false-positive cluster.
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Fig. 2 Effect of cannabidiol (CBD) on brain activation compared with placebo in participants at clinical high risk of psychosis (CHR) and
healthy control participants. a Clusters where activation differed across the three groups in a linear relationship during fear processing. In the
parahippocampal region (red/yellow), activation was greatest in the group of clinical high risk participants receiving placebo, lowest in healthy
controls and intermediate in the CBD group. In the striatum (blue/green), activation was greatest in healthy controls, lowest in participants at clinical
high risk receiving placebo and intermediate in participants at clinical high risk receiving CBD. The right side of the brain is shown on the right of the
images. b–e Median activation in each group in b the left parahippocampal gyrus, c the right parahippocampal gyrus, d left caudate head and
e right putamen during fear processing in arbitrary units as indexed using the median sum of squares ratio. The sum of squares ratio statistic refers to
the ratio of the sum of squares of deviations from the mean image intensity due to the model (over the whole time series) to the sum of squares of
deviations due to the residuals.
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expected to be more salient than neutral (innocuous)
stimuli. Misattribution of salience by CHR individuals in
this context may underlie the deficits in recognising and
interpreting the emotions and intentions of others82,83.
This, in turn, may contribute to anxiety, paranoia and the
development of attenuated psychotic symptoms37, which
are characteristic of the CHR state.
While the present study and previous work points
towards potential neurophysiological mechanisms
underlying the antipsychotic and anxiolytic effects of
CBD, the precise molecular mechanism(s) remain
incompletely understood. Preclinical and in vitro work
suggests that the effects of CBD may be mediated by
various mechanisms, including negative allosteric mod-
ulation of the CB1 receptor84, inhibition of anandamide
hydrolysis85, actions on 5-HT1A receptors86, vanilloid
type 1 receptors85, GPR55 receptors87,88, modulation of
the glutamate system89 and various other mechan-
isms90,91. Further preclinical evidence points to neuro-
protective, antioxidant and anti-inflammatory properties
of CBD10. However, direct evidence in humans is lacking.
Although functional neuroimaging results are almost
certainly downstream from primary molecular effects87,
they offer crucial insight into the neural substrates and
systems-level effects of CBD in vivo in target patient
populations.
Our results should be considered in the context of
certain limitations, one of which was the absence of a
within-subject design. The possibility that between-
group differences were attributable to between-subject
variability, as opposed to an effect of CBD, cannot
therefore be completely excluded. Because we used an
ROI approach, focussing on the striatum/pallidum and
medial temporal lobe, we were not able to determine
whether CBD had effects in other areas involved in
emotional processing. Ideally, we would also have shown
that effects of CBD on brain function were accompanied
by effects on anxiety or psychotic symptoms. However,
the study was powered to detect neural, as opposed to
symptomatic effects. Future studies in larger samples are
therefore required to investigate effects on symptoms. In
addition, while we demonstrated that CBD has effects on
the striatum and medial temporal cortex, whether these
effects are mechanistically related to its antipsychotic or
even anxiolytic effects remains unclear, as we did not
examine these in the present study. This study also only
reports on the acute effects of CBD, and it is possible
that the effects may differ after a sustained period of
treatment. It could also be argued that a parallel group of
healthy controls receiving CBD would have helped to
disentangle potential placebo effects. However, the
healthy control group in the current study was primarily
included to help determine whether the effects of CBD
on brain activation were localised to those regions where
CHR patients under placebo conditions showed dys-
function compared to controls and whether the effect
direction was consistent with normalisation of brain
function. Absence of group differences in task perfor-
mance may arguably be considered as a limitation of the
present study. It is worth noting that the fMRI paradigm
that we employed did not involve an explicit measure-
ment of accuracy of fear perception. Instead, participants
were instructed to indicate (via button press) the gender
of the faces (expressing different levels of fear), thus
involving the implicit processing of fearful faces. The
behavioural task data (gender discrimination accuracy
and reaction times) therefore indexed a general measure
of participants’ attention to the task, as well as the extent
to which the underlying emotional valence (fearful sti-
muli) modulated the accuracy of appraisal of gender, and
were not significantly different between groups. This was
because the study was designed to investigate group
differences in brain activation (neurophysiological
response) while processing fearful facial stimuli rather
than in task performance (behavioural response) and was
powered as such. Absence of significant group difference
in task performance does not preclude significant group
difference in neurophysiological response92 and may
even be desirable, as it minimises the risk of group dif-
ferences in neurophysiological response being a non-
specific consequence of differences in task perfor-
mance93. Therefore, the differences that we observed in
brain function may be argued to be not confounded by
an effect of differences between groups in performance
levels. Nevertheless, one cannot underestimate the
merits of using an fMRI task that can also probe per-
formance differences in the accuracy of fear perception,
which warrants investigation in appropriately designed
future studies. In terms of our patient group, we
recruited a representative sample of CHR individuals as
typically found in specialist CHR services94. However,
CHR populations are clinically heterogeneous and it
therefore remains possible that our results would differ
in samples stratified, for example, by the three compo-
nent subgroups of the CAARMS. Such an investigation
would, however, require significantly larger sample sizes,
which will likely be achieved only through the future use
of large multi-centre studies. Finally, it may also be
argued that statistically non-significant numerical group
differences in THC-positive urine drug screen results
between the CHR groups may have affected the differ-
ences in brain activation that we detected between the
placebo treatment vs the CBD group. It is worth noting
that all CHR participants satisfied the diagnosis of CHR
state irrespective of whether they tested positive or
negative on urine drug screen tests on the study day. All
participants were advised to abstain from using cannabis
for 96 h and confirmed as such verbally on the study day
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and yet tested positive on urine drug screen, reflecting
the longer elimination period of THC and its metabolites
in urine in cannabis users95. However, none of the par-
ticipants were clinically intoxicated at the time of pre-
senting on the morning of the study day and clearly were
not so by the time of their fMRI scanning, which
occurred around 3–4 h later. Therefore, in our view it is
very unlikely that group differences in urine positive
CHR individuals would have had a substantial effect on
our results in the absence of clinically evident intoxica-
tion in urine positive individuals and the small numbers
who tested positive per CHR treatment group. Never-
theless, we cannot be absolutely certain that group dif-
ferences in the numbers of CHR participants who tested
positive for THC on urine drug screen, although not
statistically significant, did not affect group differences
(CHR-PLB vs CHR-CBD) in brain activation that we
detected.
Despite these limitations, this study is the first to
demonstrate that a single dose of CBD modulates activation
of the medial temporal cortex and striatum during fear
processing in CHR patients. In showing that CBD mod-
ulates function of the neural circuitry directly implicated in
psychosis onset23,74, these results add to previous evidence
that CBD may be a promising novel therapeutic for patients
at CHR19,66,96. Our results also support further investigation
of the potential utility of CBD outside of the CHR field in
other populations, such as in those with anxiety.
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